Norme de certification: Conforme à la/aux monographie(s) de la pharmacopée EP
IUPAC Name: sodium 4-[[(1R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxopyrimidin-1-yl]-1-phenylethyl]amino]butanoate
EC Number: 692-765-8
Molecular Weight: 653.6
Chemical Formula: C₃₂H₂₉F₅N₃NaO₅
CAS Number: 832720-36-2
Type de formulation: Forme solide amorphe
Statut réglementaire: Matériau en phase de développement / soumission réglementaire
Status: Pipeline
Therapeutic cat.: Other
Polymorphic form: Amorphous

Autres informations

Description supplémentaire:

Established in 1935 and based in the Greater Poland Voivodeship, Polpharma is a manufacturer and service provider of active pharmaceutical ingredients spanning prophylactic biological products, central nervous system drugs, cardiovascular system drugs and related APIs, offering CDMO contract manufacturing to markets across North America, Latin America, Western and Eastern Europe, Australasia, Asia, the Middle East and Africa. Drawing on 75 years of experience in the API business, Polpharma API covers the full value chain from R&D through production and supply chain management to project management, operating from a European base with R&D and two manufacturing plants, and specializes in high-potency APIs (OEB 5&6), high-potency ADC payloads, advanced linker technologies, customizable ADC development solutions, cryogenic reactions and oligonucleotides. The company is recognized for international certification, an experienced R&D team, strong reputation, high-quality service and a genuinely global market presence.